+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID07657676

Evaluating Mazdutides Effect on Coronary Plaque Progression in Adults with Coronary Atherosclerosis and Overweight or Obesity in a Randomized, Placebo-Controlled Trial

Led by China National Center for Cardiovascular Diseases · Updated on 2026-10-13

116

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effect of mazdutide, a dual GLP-1GCG receptor agonist, on coronary plaque progression in adults with coronary atherosclerosis who are overweight or obese. This phase 4, multicenter, randomized, double-blind, placebo-controlled trial aims to assess changes in coronary artery plaque volume and related metabolic and inflammatory markers over a 52-week period. The study also includes a PET-CT substudy to explore plaque inflammation. Participants receive either mazdutide or placebo by subcutaneous injection once weekly, starting at 2 mg for 4 weeks, increasing to 4 mg for the next 4 weeks, and then 6 mg until week 52. The trial compares the changes in non-calcified plaque volume and other plaque characteristics using coronary computed tomography angiography CCTA. The substudy uses 18F-NaF PETCT imaging to evaluate plaque inflammation. During the 52 weeks, participants undergo CCTA scans at baseline and week 52 to measure plaque volume and composition, along with assessments of metabolic parameters, inflammatory biomarkers, and clinical outcomes. Safety and adherence are monitored throughout the study. The total participation duration is about one year, including all study visits and evaluations.

CONDITIONS

Brief Title

Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity

Research Team

X

Xiao Wang

F

Fang Luo

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here